Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rubicon ResearchNSE:RUBICON +1.45%18 Market Cap is ₹237,175 Mil as of Jul. 19, 2026. GuruFocus rates NSE:RUBICON with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Rubicon Research ranks better than 87.29% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Rubicon Research's share price for the quarter that ended in Mar. 2026 was ₹772.8. Rubicon Research's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 165 Mil. Therefore, Rubicon Research's market cap for the quarter that ended in Mar. 2026 was ₹127,319 Mil.
Rubicon Research's quarterly market cap
increased
from Jun. 2025 (₹0 Mil) to Dec. 2025 (₹112,154 Mil) and
increased
from Dec. 2025 (₹112,154 Mil) to Mar. 2026 (₹127,319 Mil).
Rubicon Research's annual market cap
stayed the same
from Mar. 2024 (₹0 Mil) to Mar. 2025 (₹0 Mil) but then
increased
from Mar. 2025 (₹0 Mil) to Mar. 2026 (₹127,319 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Rubicon Research's Enterprise Value for Today is ₹236,674 Mil.
Rubicon Research (NSE:RUBICON) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Rubicon Research Market Cap Related Terms
Rubicon Research Market Cap Historical Data
* Premium members only.
The historical data trend for Rubicon Research's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:RUBICON vs LLY, JNJ, ABBV: Market Cap Comparison
For the Drug Manufacturers - General subindustry, Rubicon Research's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rubicon Research Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rubicon Research's Market Cap distribution charts can be found below:
* The bar in red indicates where Rubicon Research's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Rubicon Research's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rubicon Research (NSE:RUBICON) has a Market Cap of ₹237,175 Mil as of Jul. 19, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Rubicon Research and its competitors. According to the industry distribution chart, Rubicon Research ranks #130 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 12.7%.
Is Rubicon Research's Market Cap too high?
Rubicon Research's current Market Cap is ₹237,175 Mil. Based on the distribution chart, Rubicon Research ranks #130 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Rubicon Research has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's Market Cap compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Rubicon Research ranks #130 out of 1023 companies for Market Cap. This places Rubicon Research in the top 13% of its industry — outperforming the majority of peers. The industry median Market Cap is 216.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 216.46, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Rubicon Research and its competitors. For the Drug Manufacturers industry, the median Market Cap is 216.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Research's current Market Cap is ₹237,175 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current Market Cap of ₹237,175 Mil. The current Market Cap is ₹237,175 Mil. Rubicon Research's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current Market Cap is ₹237,175 Mil as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
18GF Score
Get the complete analysis for NSE:RUBICON
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RUBICON has been successfully added to your 
